MedTrace Logo

Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)

NCT00691522 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-01-09

No results posted yet for this study

Summary

This is a phase II, multicenter, open-label, imaging study of hCRF in the reduction of PBE in patients with primary malignant or metastatic brain tumors. Approximately 30 to 60 patients will be assigned to 1 of 3 treatment groups and receive study drug for up to 28 days

Conditions

  • Peritumoral Brain Edema
  • PRIMARY MALIGNANT and METASTATIC BRAIN TUMORS

Interventions

DRUG

Xerecept

Sponsors & Collaborators

  • Celtic Pharma Development Services

    collaborator INDUSTRY

  • PharmaNet

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-08-31
Completion
2009-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00691522 on ClinicalTrials.gov